Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters
AssigneeBTG International Limited
InventorsLaurence S. Harbige, Michael J. Leach, Paul Barraclough
Life of this patent
Estimating the term…
Abstract
A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R1 is the fatty acyl group of an essential polyunsaturated fatty acid selected from γ-linolenoyl, γ-dihomolinolenoyl and arachidonoyl.
Claims28
A method of treating a patient in need of therapy for dysregulation of TGF-β1, IL-1β, IL4, IL5, IL6, IL8, IL10, IL13 and/or γ-IFN comprising administering to that patient a therapeutically effective dose of a monoglyceride of general formula I
- wherein R1 is the fatty acyl group of an essential polyunsaturated fatty acid selected from γ-linolenoyl, γ-dihomolinolenoyl and arachidonoyl.
A composition for use in the method of the present invention comprising a compound of formula I together with a pharmaceutically or nutraceutically acceptable carrier, coating, capsule, diluent and/or preservative.
A composition as claimed in claim 17 comprising a preservative which is an antioxidant or inhibitor of transesterification.
A method of treating a patient in need of therapy for dysregulation of TNF-α comprising administering to that patient a therapeutically effective dose of a monoglyceride of general formula I
- wherein R1 is the fatty acyl group of an essential polyunsaturated fatty acid selected from γ-linolenoyl, γ-dihomolinolenoyl.
Dependencies are inferred from the claim text.